Biogen Sets Aside Cash For Business Development, Expects New Launches In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The spec pharma had a strong year and will continue to rely on new product launches going forward, but hopes to bolster its pipeline with early-stage add-ons.
You may also be interested in...
FDA/IoM “Uncertainty” Conference Adds Uncertainty to Biogen Growth Plans For Tysabri
An FDA/Institute of Medicine workshop on characterizing and communicating the uncertainty inherent in risk/benefit decisions touched on an important topic for every sponsor. But two “case studies” included points a very particular interest to Biogen Idec, and to sponsors in the COPD class.
Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese
Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.
At J.P. Morgan, Ironwood, Shire and Biogen Idec Contemplate What’s Next
A trio of companies offer insight into their latest strategies from interviews and presentations at the recent J.P. Morgan Healthcare conference: Ironwood’s development pipeline includes seven GI drugs; R&D consolidation and pipeline review at Shire; Biogen preps for hemophilia market and MS pricing pressures.